Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atea Pharmaceuticals, Inc. - common stock (NQ:AVIR)

4.240 -0.220 (-4.93%)
Delayed Quote Updated: 1:12 PM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Atea Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 Next >
News headline image
Atea (AVIR) Q2 2026 Earnings Call Transcript ↗
HCV regimen met non-inferiority with 8-week dosing for non-cirrhotic patients. 
Via The Motley Fool
Topics Earnings
News headline image
Atea Pharmaceuticals Q2 Earnings Call Highlights ↗
Atea Pharmaceuticals (NASDAQ:AVIR) reported positive top-line results from its Phase III C-BEYOND trial of bemnifosbuvir/ruzasvir for chronic hepatitis C virus, saying the study met its primary and... 
Via MarketBeat
Topics Earnings
News headline image
Atea Pharmaceuticals Q1 Earnings Call Highlights ↗
Atea Pharmaceuticals (NASDAQ:AVIR) said it remains on track for two key Phase 3 hepatitis C readouts in 2026 while advancing a newer hepatitis E program aimed at immunocompromised patients with no... 
Via MarketBeat
Topics Earnings
Atea Pharmaceuticals (NASDAQ:AVIR) Q1 Loss Narrows as HCV and HEV Pipeline Catalysts Loom ↗
Via Chartmill
Atea Pharmaceuticals (NASDAQ:AVIR) Reports Q4 2025 Results as HCV and HEV Pipeline Advance ↗
Via Chartmill
News headline image
Earnings Scheduled For November 12, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Recap: Atea Pharmaceuticals Q4 Earnings ↗
 
Via Benzinga
News headline image
Atea Pharma (AVIR) Earnings Call Transcript ↗
Atea Pharma (AVIR) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround ↗
CarMax runs a nationwide network of used car stores and digital channels, offering multi-channel sales and financing to U.S. consumers. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter. ↗
This clinical-stage biotech develops therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition. 
Via The Motley Fool
News headline image
Atea Pharmaceuticals Earnings Preview ↗
 
Via Benzinga
News headline image
Atea Pharmaceuticals's Earnings Outlook ↗
 
Via Benzinga
News headline image
Earnings Preview For Atea Pharmaceuticals ↗
 
Via Benzinga
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
Via Chartmill
News headline image
Atea Pharma (AVIR) Earnings Call Transcript ↗
Atea Pharma (AVIR) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Atea Pharmaceuticals Inc (NASDAQ:AVIR) Reports Q3 2025 Financial Results and Business Update ↗
Atea Pharmaceuticals reports Q3 2025 financials, focusing on its advancing Phase 3 HCV program and pipeline expansion into hepatitis E virus (HEV). 
Via Chartmill
News headline image
Atea Pharmaceuticals Earnings Preview ↗
 
Via Benzinga
News headline image
Atea (AVIR) Q2 Loss Narrows 8% ↗
Via The Motley Fool
News headline image
Top movers in Wednesday's pre-market session ↗
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial ↗
Atea Pharma posted a Q4 loss of $0.40 per share, cut 25% of its workforce, and is launching a Phase 3 HCV trial while facing analyst skepticism over its drug. 
Via Benzinga
News headline image
After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study ↗
Atea Pharmaceuticals reports 98% SVR12 in a Phase 2 hepatitis C study, supporting an eight-week treatment plan with bemnifosbuvir and ruzasvir. 
Via Benzinga
News headline image
Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus ↗
Atea Pharmaceuticals' Phase 3 SUNRISE-3 trial for bemnifosbuvir in COVID-19 patients did not meet the primary endpoint. The company remains focused on its hepatitis C combination therapy. 
Via Benzinga
News headline image
Adobe, SelectQuote, Similarweb And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 6, 2025 ↗
 
Via Benzinga
News headline image
Atea Pharmaceuticals Shares Promising Data From Therapy Study For Hepatitis C Virus ↗
Atea Pharmaceuticals announces 97% SVR12 in Phase 2 HCV study of bemnifosbuvir. Data shows high efficacy, safety, and low resistance risk. 
Via Benzinga
News headline image
AVIR Stock Earnings: Atea Pharmaceuticals Misses EPS for Q1 2024 ↗
AVIR stock results show that Atea Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
5 Under 10: Low Share Price, Debt Free, Lots Of Cash ↗
A look at five low-priced stocks with lots of cash per share, and no or very low debt. Most of them have very low-cap stocks and should be considered very speculative. 
Via Talk Markets
News headline image
Atea Pharmaceuticals' Hepatitis C Virus Candidate Shows Efficacy ↗
Atea Pharmaceuticals Inc (NASDAQ: AVIR) reported initial data from the first 52 patients in the lead-in cohort of its Phase 2 combination eight-week study of bemnifosbuvir and ruzasvir (RZR) for 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.